3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
7
Recurrence
5
Neoplasms
2
Leukemia, Myeloid, Acute
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Uterine Diseases
1
Primary Myelofibrosis
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Genital Diseases
1
COVID-19
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled
NCT04534725
2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3
Completed
441 enrolled